Information Provided By:
Fly News Breaks for February 21, 2020
BXRX
Feb 21, 2020 | 06:50 EDT
Piper Sandler analyst David Amsellem raised the firm's price target on Baudax Bio to $14 from $11 and reiterates an Overweight rating on the shares. Baudax Bio announced the FDA approval of Anjeso, its intravenous form of the nonsteroidal anti-inflammatory drug for moderate-to-severe pain either alone or in combination with another non-NSAID's, Amsellem tells investors in a research note. The analyst continues to believe that Anjeso will emerge as a valued addition to a treatment landscape "that is very much in need of more non-opioid options."
News For BXRX From the Last 2 Days
There are no results for your query BXRX